Theratechnologies Inc. (THTX)
THTX Stock Price Chart
Explore Theratechnologies Inc. interactive price chart. Choose custom timeframes to analyze THTX price movements and trends.
THTX Company Profile
Discover essential business fundamentals and corporate details for Theratechnologies Inc. (THTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
13 Feb 2009
Employees
103.00
Website
https://www.theratech.comCEO
Paul Lévesque
Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
THTX Financial Timeline
Browse a chronological timeline of Theratechnologies Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 Apr 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 9 Oct 2025
Earnings released on 9 Jul 2025
EPS came in at -$0.09 falling short of the estimated -$0.01 by -516.44%, while revenue for the quarter reached $17.73M , missing expectations by -34.07%.
Earnings released on 9 Apr 2025
EPS came in at $0.00 falling short of the estimated $0.03 by -92.27%, while revenue for the quarter reached $19.05M , missing expectations by -20.37%.
Earnings released on 26 Feb 2025
EPS came in at -$0.09 falling short of the estimated $0.05 by -280.00%, while revenue for the quarter reached $25.00M , beating expectations by +3.10%.
Earnings released on 10 Oct 2024
EPS came in at $0.06 surpassing the estimated $0.03 by +100.00%, while revenue for the quarter reached $22.60M , missing expectations by -27.54%.
Earnings released on 10 Jul 2024
EPS came in at $0.02 surpassing the estimated $0.01 by +220.00%, while revenue for the quarter reached $22.01M , beating expectations by +1.38%.
Earnings released on 10 Apr 2024
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%, while revenue for the quarter reached $16.09M , missing expectations by -19.97%.
Earnings released on 21 Feb 2024
EPS came in at -$0.08 surpassing the estimated -$0.24 by +66.67%, while revenue for the quarter reached $23.45M , beating expectations by +0.39%.
Earnings released on 26 Sept 2023
EPS came in at -$0.03 surpassing the estimated -$0.29 by +89.66%, while revenue for the quarter reached $20.86M , missing expectations by -10.72%.
Stock split effective on 31 Jul 2023
Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Jul 2023
EPS came in at -$0.40 falling short of the estimated -$0.10 by -300.00%, while revenue for the quarter reached $17.55M , missing expectations by -13.64%.
Earnings released on 12 Apr 2023
EPS came in at -$0.44 falling short of the estimated -$0.38 by -15.79%, while revenue for the quarter reached $19.91M , missing expectations by -8.51%.
Earnings released on 28 Feb 2023
EPS came in at -$0.36 falling short of the estimated $0.08 by -550.00%, while revenue for the quarter reached $21.42M , missing expectations by -0.54%.
Earnings released on 13 Oct 2022
EPS came in at -$0.32 falling short of the estimated -$0.12 by -166.67%, while revenue for the quarter reached $20.81M , beating expectations by +0.70%.
Earnings released on 14 Jul 2022
EPS came in at -$0.96 falling short of the estimated -$0.38 by -152.63%, while revenue for the quarter reached $19.27M , missing expectations by -5.08%.
Earnings released on 13 Apr 2022
EPS came in at -$0.36 falling short of the estimated -$0.07 by -414.29%, while revenue for the quarter reached $18.56M , missing expectations by -13.69%.
Earnings released on 24 Feb 2022
EPS came in at -$0.40 falling short of the estimated -$0.07 by -471.43%, while revenue for the quarter reached $18.75M , missing expectations by -8.52%.
Earnings released on 13 Oct 2021
EPS came in at -$0.40 falling short of the estimated -$0.07 by -471.43%, while revenue for the quarter reached $17.85M .
Earnings released on 15 Jul 2021
EPS came in at -$0.28 falling short of the estimated -$0.07 by -300.00%, while revenue for the quarter reached $17.79M .
Earnings released on 14 Apr 2021
EPS came in at -$0.28 falling short of the estimated -$0.05 by -460.00%, while revenue for the quarter reached $15.43M , beating expectations by +1.01%.
Earnings released on 25 Feb 2021
EPS came in at -$0.28 falling short of the estimated -$0.06 by -366.67%, while revenue for the quarter reached $19.12M .
Earnings released on 15 Oct 2020
EPS came in at -$0.36 falling short of the estimated -$0.06 by -500.00%, while revenue for the quarter reached $14.05M , beating expectations by +21.21%.
THTX Stock Performance
Access detailed THTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.